Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023:133:103-105.

THE GORDON WILSON LECTURE: RAPID COVID-19 VACCINE DEVELOPMENT AND THE FUTURE OF VACCINOLOGY

Barney S Graham  1
Affiliations

THE GORDON WILSON LECTURE: RAPID COVID-19 VACCINE DEVELOPMENT AND THE FUTURE OF VACCINOLOGY

Barney S Graham. Trans Am Clin Climatol Assoc. 2023.
No abstract available

PubMed Disclaimer

Figures

Fig. 1.
Fig. 1.
Vaccine-related technology development. Rapid COVID-19 vaccine development was a consequence of many years of cumulative basic research advances driven largely by efforts to make an AIDS vaccine over the last 40 years. Abbreviations: RSV, respiratory syncytial virus; VAERD, Vaccine-associated enhanced respiratory disease.
Fig. 2.
Fig. 2.
Prototype pathogen approach for pandemic preparedness. There are currently 26 virus families known to be associated with human infection. Here they are organized by entry mechanisms and class of fusion protein used by enveloped viruses. Arteriviridae are added here in parentheses because they are not known to infect humans, but they are in the Nidovirales order (like coronaviruses) and can cause a hemorrhagic fever syndrome in nonhuman primates. They have distinct characteristics compared to the other virus families listed and not much is known about basic aspects of virology and immunity. It is recommended that prototypic viruses selected from viral families and functional groups are studied in depth to prepare candidate surveillance tools, vaccines, monoclonal antibodies, antivirals, diagnostics, and reagents prior to any future threats. The basic research findings would inform approaches to other family members and guide generalizable solutions that may be applicable across virus families. Centers with the capabilities listed in the middle should be established to support process development, pilot scale manufacturing, and preclinical and clinical evaluation of candidate countermeasures identified by pathogen-directed research.
See this image and copyright information in PMC

References

    1. Graham BS, Sullivan NJ. Emerging viral diseases from a vaccinology perspective: preparing for the next pandemic. Nat Immunol. 2018;19(1):20–8. - PMC - PubMed
    1. Ledgerwood JE, Graham BS. DNA vaccines: a safe and efficient platform technology for responding to emerging infectious diseases. Hum Vaccin. 2009;5(9):623–6. - PubMed
    1. Ledgerwood JE, Sullivan NJ, Graham BS. Chimpanzee adenovirus vector ebola -vaccine—preliminary report. N Engl J Med. 2015;373(8):776. - PubMed
    1. Kennedy SB, Bolay F, Kieh M, Grandits G, Badio M, Ballou R, et al. Phase 2 -placebo-controlled trial of two vaccines to prevent ebola in Liberia. N Engl J Med. 2017;377(15):1438–47. - PMC - PubMed
    1. Henao-Restrepo AM, Camacho A, Longini IM, Watson CH, Edmunds WJ, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ca Suffit!) Lancet. 2017;389(10068):505–18. - PMC - PubMed

Substances

LinkOut - more resources